FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula (I), where each of n and m independently equals 1; R1 is halogen or a group selected from a straight or branched (C1-C8)alkyl and heterocyclyl, selected from piperidinyl and tetrahydropyranyl, where piperidinyl is optionally substituted with (C1-C6)alkyl and (C3-C6)cycloalkyl; or R1 is NR7R8, where each R7 and R8 independently represents hydrogen or a group, selected from a straight or branched (C1-C8)alkyl, heterocyclyl, selected from piperidinyl and optionally substituted methyl; or, taken together with a nitrogen atom with which they are bonded, R7 and R8 can form optionally substituted 3-8-member heterocyclyl, optionally having one additional heteroatom or heteroatomic group selected from O, N and NH, optionally substituted with halogen; each of R2 and R3 independently represents hydrogen, halogen or optionally substituted group, selected from a straight or branched (C1-C8)alkyl and heterocyclyl, selected from imidazolidine, substituted -COCH3, -C=O, -CH2-OCH3, -CH3; or each of R2 and R3 independently represents NR17R18, where R17 and R18 independently denote hydrogen or optionally substituted group, selected from a straight or branched (C1-C8)alkyl, optionally substituted -NH-COCH3, -NHCOOCH3, -N(CH3)2; or R17 represents hydrogen and R18 represents COR22, where R22 denotes OR23 or optionally substituted group, selected from a straight or branched (C1-C8)alkyl, where R23 is straight or branched (C1-C8) alkyl, each of R4 and R5 is independently hydrogen or halogen; Rx is hydrogen; R6 denotes phenyl, optionally substituted with halogen; or a pharmaceutically acceptable salt thereof. Invention relates to a method of inhibiting activity in vitro of Raf, which involves bringing said receptor into contact with an effective amount of compound of formula (I). Compound of formula (I) or a pharmaceutically acceptable salt thereof are intended for use as a medicinal agent or in a pharmaceutical composition, with activity against a malignant tumour.
EFFECT: technical result is thiazolylphenyl-benzenesulfonamido derivatives as Raf kinase inhibitors.
10 cl, 1 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | 2015 |
|
RU2683309C2 |
| AMIDES OF CONDENSED PIPERIDINE AS MODULATORS OF ION CHANNELS | 2014 |
|
RU2741810C2 |
| PROTEIN KINASE INHIBITORS FOR ENHANCING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2019 |
|
RU2822216C2 |
| NEW COMPOUNDS FOR THE TREATMENT OF MAMMALIAN INFECTIONS | 2019 |
|
RU2798336C2 |
| (AZA)INDOLE-, BENZOTHIOPHENE- AND BENZOFURAN-3-SULPHONAMIDES | 2017 |
|
RU2767904C2 |
| JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2707870C2 |
| N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2821520C2 |
| FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | 2014 |
|
RU2671979C2 |
| MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH | 2019 |
|
RU2788000C2 |
